 This is an open-label participants and researchers are aware about the treatment, participants are receiving, single-dose, single-center, parallel group a medical research study comparing the response in 2 or more groups of participants receiving different interventions study. This study consists of a Screening Period within 21 days prior to admission into the study center on Day -1, followed by 2 treatment periods for ESRD participants Group A Treatment Period 1: rivaroxaban will be administered 2 hours before the start of a 4-hour hemodialysis session on Day 1; Treatment Period 2: rivaroxaban will be administered 3 hours after the completion of a 4-hour hemodialysis session on Day 1, or 1 treatment period for healthy participants Group B single oral dose of rivaroxaban will be administered on Day 1. Each treatment period will have duration of 4 days. For ESRD participants, the 2 treatments periods will be separated by a washout period of at least 7 days and a maximum of 14 days. The total study duration for ESRD participants is approximately 43 days. The total study duration for healthy participants is approximately 25 days. Blood samples will be collected to assess pharmacokinetic and pharmacodynamic parameters. Participants safety will be monitored throughout the study. 